期刊
BLOOD
卷 127, 期 7, 页码 801-809出版社
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2015-09-618538
关键词
-
类别
资金
- American Heart Association [15PRE23010014]
- R01 grants from the National Institutes of Health, National Heart, Lung, and Blood Institute [HL069438, HL116340]
- National Institute of Diabetes and Digestive and Kidney Diseases [DK056638]
Sickle cell disease (SCD) is a severe genetic blood disorder characterized by hemolytic anemia, episodic vaso-occlusion, and progressive organ damage. Current management of the disease remains symptomatic or preventative. Specific treatment targeting major complications such as vaso-occlusion is still lacking. Recent studies have identified various cellular and molecular factors that contribute to the pathophysiology of SCD. Here, we review the role of these elements and discuss the opportunities for therapeutic intervention.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据